Market News AIOpen the app

Prelude Therapeutics shared its third quarter 2026 results, showing a solid cash position and progress in its studies.

ResultsRead the original at globenewswire.com
Good for PRLD

The cash expected to last into the second quarter of 2028 and Lilly's study agreement give Prelude time and a partner to test PRT13722. The studies remain early, with no patient results reported.

PRLD · Prelude Therapeutics

AI read · Good for PRLD

The AI's read

That cash gives Prelude time to keep its drug studies running. Lilly's agreement adds a way to test PRT13722 with 2 Lilly medicines. But the studies are still in Phase 1, and the report gives no patient results.

LLY · Eli Lilly and Company

AI read · Neutral

The connection

Lilly agreed to test Prelude's drug with Verzenio and Inluriyo. No study results or other clear change to Lilly's business are reported.

Get alerts for PRLD

Follow Prelude Therapeutics (PRLD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PRLD
Free on the App Store and Google Play, or on the web.